<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980496</url>
  </required_header>
  <id_info>
    <org_study_id>N N402 462539</org_study_id>
    <secondary_id>4625/B/P01/2010/39</secondary_id>
    <nct_id>NCT03980496</nct_id>
  </id_info>
  <brief_title>Effects of Different Omeprazole Dosing on Gastric pH in Non-variceal Upper Gastrointestinal Bleeding</brief_title>
  <official_title>Effects of Different Omeprazole Dosing on Gastric pH in Non- Variceal Upper Gastrointestinal Bleeding: A Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Bialystok</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Centre, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Bialystok</source>
  <brief_summary>
    <textblock>
      The aim of the study is to identify the best method of omeprazole (OME) application with
      respect to intragastric pH, cytochrome P450 2C19 (CYP2C19) genotype and phenotype.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients with non-variceal upper gastrointestinal bleeding (NVUGIB) are prospectively
      enrolled. After the achievement of endoscopic hemostasis, the patients are randomized to
      40-mg intravenous (i.v.) OME bolus injection every 12 h or 8-mg/h continuous i.v. infusion
      for 72 h after an 80-mg i.v. OME bolus administration. The intragastric pH is recorded for 72
      h. The CYP2C19 variant alleles (*2, *3, *17) are analyzed and the serum concentrations of OME
      and 5-hydroxyomeprazole (5-OH OME) are determined. The diagnosis of Helicobacter pylori
      infection was based on the results of the rapid urease test performed on stomach mucosa
      biopsies (antrum and angle) and on the results of the stool antigen test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2010</start_date>
  <completion_date type="Actual">June 8, 2013</completion_date>
  <primary_completion_date type="Actual">June 8, 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intragastric pH in non-variceal upper gastrointestinal bleeding patients treated with omeprazole regarding: Percentage of time at pH &gt;4.0 and pH &gt;6.0</measure>
    <time_frame>72 hours</time_frame>
    <description>intragastric pH profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intragastric pH in non-variceal upper gastrointestinal bleeding patients treated with omeprazole regarding: pH at specified time after the initial OME 80 mg i.v. bolus</measure>
    <time_frame>72 hours</time_frame>
    <description>intragastric pH profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intragastric pH in non-variceal upper gastrointestinal bleeding patients treated with omeprazole regarding: Helicobacter pylori infection</measure>
    <time_frame>72 hours</time_frame>
    <description>intragastric pH profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intragastric pH in non-variceal upper gastrointestinal bleeding patients treated with omeprazole regarding: CYP2C19 variant alleles (*2, *3, *17)</measure>
    <time_frame>72 hours</time_frame>
    <description>intragastric pH profiles</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Non-variceal Upper Gastrointestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>omeprazole infusion (OI) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OI group is then treated with an 8-mg/h continuous i.v. infusion of OME for 72 h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omeprazole bolus (OB) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After successful endoscopic hemostasis, the patients are given an 80-mg i.v. omeprazole bolus. The OB group receives a 40-mg i.v. bolus of OME every 12 h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <arm_group_label>omeprazole bolus (OB) group</arm_group_label>
    <arm_group_label>omeprazole infusion (OI) group</arm_group_label>
    <other_name>endoscopic treatment of non-variceal upper gastrointestinal bleeding</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent must be obtained before any treatment or assessment is
             performed

          -  patients admitted with upper gastrointestinal bleeding (UGIB) symptoms to the
             Emergency Department of the University Hospital of Bialystok (Bialystok, Poland)

        Exclusion Criteria:

          -  pregnancy

          -  age &gt;90 years

          -  lack of written consent

          -  recent treatment with certain medications, including PPIs, H2-receptor antagonists
             (H2RA), antacids, steroids, oral contraceptives, clopidogrel, prasugrel and
             clarithromycin

          -  the presence of variceal UGIB

          -  history of surgery of upper gastro-intestinal tract
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrzej Dabrowski, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Bialystok</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology and Internal Medicine, Medical University of Bialystok</name>
      <address>
        <city>Bia≈Çystok</city>
        <state>Podlaskie</state>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/abs/10.1111/1751-2980.12393</url>
    <description>J Dig Dis. 2016 Sep;17(9):588-599</description>
  </link>
  <results_reference>
    <citation>Chwiesko A, Charkiewicz R, Niklinski J, Luczaj W, Skrzydlewska E, Milewski R, Baniukiewicz A, Wroblewski E, Rosolowski M, Dabrowski A. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study. J Dig Dis. 2016 Sep;17(9):588-599. doi: 10.1111/1751-2980.12393.</citation>
    <PMID>27518195</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CYP2C19</keyword>
  <keyword>Helicobacter pylori</keyword>
  <keyword>non-variceal upper gastrointestinal bleeding</keyword>
  <keyword>intragastric pH</keyword>
  <keyword>proton pump inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

